Objective. The study aim was to investigate the diagnostic value of preoperative serum tumor markers in patients with adnexal masses. Methods. Study included all (358) consecutive patients treated for adnexal tumors at the Clinic of Ob/Gyn, Clinical Center of Serbia in 12 months. Tumor marker levels (Ca 125, CEA, HE 4, Ca 19.9, and Ca 15.3), taken from all women on admission, were compared with postoperative histopathological findings of extracted tumors. Results. Women with malignant tumors had the highest levels of Ca 125, CEA, and HE 4 (p<0.01). Mucinous adenocarcinoma produced the highest amounts of Ca 19.9 and CEA. Ca 15.3 was the highest in women with endometrioid carcinoma. There were no significant differences in the levels of all examined tumor markers (p>0.05) between women with benign and borderline tumors. Ca 125, HE 4, and Ca 15.3 can discriminate the malignant from other tumor types well. The highest sensitivity, specificity, positive and negative predictive values (91.04%, 87.6%, 67.9%, 77.2%, respectively) were achieved for the combination of Ca 125 and HE 4. Conclusions. Blood levels of examined tumor markers can be good predictors of the adnexal masses nature. For the most precise evaluation the combination of serum tumor markers should be used.
Introduction
Ovarian cancer remains the leading cause of gynecologic cancer mortality. As there is still no good screening test available, ovarian cancer is more frequently diagnosed in advanced stages [1, 2] . Good preoperative discrimination between benign and malignant ovarian tumors results in appropriate referral as well as different therapeutic approaches [3, 4] . Biomarkers have a wide range of applications in the evaluation and management of numerous tumors, including adnexal masses. Currently, serum markers are the most extensively used biomarkers in routine practice. However, few markers are elevated in preclinical or premalignant disease, and some of them are elevated even in physiological and various benign conditions, limiting their importance for estimating the risk or their use in screening of patients with adnexal tumors [5] . The aim of this study was to investigate the diagnostic value of serum tumor markers in preoperative evaluation of patients with adnexal masses.
Methods
This prospective study included all consecutive patients who were treated for adnexal tumors at the Clinic of Gynecology and Obstetrics, Clinical Center of Serbia, during the period of 12 months (from May 1, 2011 to April 30, 2012). All investigated patients signed an informed consent form. On admission, apart from detailed anamnesis, expert clinical examinations and ultrasound scans of pelvic organs, the tumor marker levels (Ca 125, CEA, HE 4, Ca 19-9 and Ca 15.3) were evaluated in all women. Referral levels used in this study were: 0-35 IU/L for Ca 125; 0-33 IU/L for Ca 19.9; 0-38 IU/L for Ca 15.3; 0-150 pmol/ml for Human Epididymal Protein 4 (HE 4) and 0.21-4.8 IU/L for Carcino-Embryonic Antigen (CEA). Postoperatively, after extraction of all masses, histopathological findings (HP) of the tumors were analyzed. First, we compared the HP findings (benign, borderline, and malignant) with all investigated tumor markers. In the next step, we assessed which tumor marker most appropriately differentiates benign, borderline, and malignant tumors. Furthermore, we analyzed the relationship between specific HP diagnoses and serum tumor marker levels. Moreover, we also investigated the relationships between all examined parameters together and the nature of the tumor type (benign/ malignant). Finally, sensitivity, specificity, positive and negative predictive values (PPV and NPV, respectively) were calculated for all the investigated serum tumor markers using the standard formulas. For statistical analysis of the obtained data we applied methods of descriptive and analytical statistics (Kolmogorov-Smirnov Z test, Friedman's parametric ANOVA, Spearman's correlation, discriminant analysis and multivariate binary logistic regression). The level of significance was p<0.05. The obtained data were analyzed using the SPSS 15.0 software.
Results
There were 358 women involved in this study. Out of all the cases, adnexal masses were malignant in 52, benign in 294, and borderline in 12 patients.
On analyzing HP findings we noticed 6 different malignant tumor diagnoses: serous adenocarcinoma, mucinous adenocarcinoma, endometrioid carcinoma, granulose cell tumor, Krukenberg tumor, and other malignant diagnoses (clear cell tumor, Mixed Muller's tumor, etc.) which were all present in just one case and therefore evaluated together. There were 7 different benign diagnoses, namely, simple ovarian cyst, endometriotic cyst, hemorrhagic cyst, teratoma, benign ovarian cystadenoma, ovarian fibrothecoma, and other diagnoses (corpus luteum, etc.) which were all present in just one case and therefore evaluated together.
HP findings were significantly and positively correlated with Ca 125 (ρ=0.272; p=0.000), HE 4 (ρ=0.296; p=0.000) and Ca 15.3 (ρ=0.468; p=0.000). Higher levels of tumor markers were associated with malignant tumors.
The mean level of Ca 125 of the examined women was 641.058 +/-2543.96 (min: 2.51; max: 20435.00; median: 27.50). There were high significant differences in the level of Ca 125 between the tumor types (p=0.000). Women with malignant tumors had the highest levels of Ca 125. However, there were no significant differences between women who had benign and borderline tumors. There were significant differences in the blood level of Ca 125 between specific tumor diagnoses (p=0.000). Ca 125 was highest in serous adenocarcinoma, as well as in the group of "other malignant tumors". However, there were no significant differences in the levels of Ca 125 within the group of malignant tumors (p=0.554) ( Table  1) . Ca 125 explained 81.3% of the cases (Figure 1 ). The laboratory recommended cutoff level of Ca 125 (35 IU/l) had the sensitivity of 83.5% and specificity of 53.6%.
The mean level of HE 4 of the examined women was 119 +/-123.23 (min: 4.00; max: 567.21; median: 57.00). There were high significant differences in the levels of HE4 between tumor types (p=0.000). Women with malignant tumors had the highest levels of HE4. Nevertheless, there were no significant differences between women who had benign and borderline tumors. When specific diagnoses were evaluated, no significant differences were found (p=0.111). Moreover, there were no significant differences in the levels of HE4 within malignant tumors (p=0.573) ( Table 1) . HE 4 explained 85.9% of the cases (Figure 1 ). The laboratory recommended cutoff level of HE 4 (150 pmol/ml) had the sensitivity of 44.4% and specificity of 86.1%.
The mean level of Ca 19.9 of the examined women was 52.85 +/-224.66 (min: 0.60; max: 1880.00; median: 10.00). There were no significant differences between tumor types (benign, borderline, malignant) regarding the level of Ca 19.9 (p=0.162). When all specific diagnoses were compared, Ca 19.9 was significantly higher in mucinous adenocarcinoma and lower in granulose cell tumor (p=0.000). However, there were no significant differences within only malignant tumors regarding the levels of Ca 19.9 (p=0.234) ( explained 49.2% of the cases (Figure 1 ). The laboratory recommended cutoff level of Ca 15.3 (38 IU/l) had the sensitivity of 37.5% and specifi city of 87.5%. The mean level of CEA of the examined women was 2.83 +/-5.97 (min: 0.00; max: 47.10; median: 1.62). There were high signifi cant differences in the levels of CEA between tumor types (p=0.000). Women with malignant tumors had the highest levels of CEA, but there were no signifi cant differences between women who had benign and borderline tumors. There were high signifi cant differences in blood levels of CEA between tumor diagnoses (p=0.000). The signifi cantly highest levels of CEA were in women with mucinous adenocarcinoma and the group of "other malignant tumors". Nevertheless, there were no signifi cant differences in the CEA levels within malignant tumors (p=0.580) ( Table  1) . CEA explained 69.5% of cases (Figure 1) . The laboratory recommended cutoff level of CEA (4.8 IU/l) had the sensitivity of 37.5% and specifi city of 87.5%.
The obtained overall percentage of sensitivity, specifi city, PPV and NPV of the examined tumor markers are presented in Table 2 .
When the fi ndings of all tumor markers were assessed together, a signifi cant model was achieved in the Enter method (χ 2 =48.868; p=0.000). The model's total classifi cation success was 85.9% and R 2 Nagelkerke was 0.671. MALIGNANCY = 3.168 -0.259 x CEA + 0.473 x HE 4
The levels of tumor markers were found to be good discriminating factors between malignant, benign, and borderline tumors. We obtained one statistically signifi cant function (eigenvalue=0.569; percentage of variance=99.3; canonical correlation=0.602; Wilks λ=0.635; χ 2 =29.759; p=0.003). From the largest group centroids for signifi cant function, it can be concluded that, Ca 125, HE 4, and Ca 15.3 have the highest scores in women with malignant tumors, and therefore, these markers discriminate malignant tumors from other tumor types well (Table 3 ).
Discussion
The prognosis of ovarian cancer is doubtful, mostly due to the late diagnosis with a very poor outcome in advanced stages. Prevention of the disease could improve prognosis, but there is still no adequate screening test for ovarian cancer [6] . Thus, the identifi cation of oncology biomarkers for screening and monitoring of occult tumors has been highly prioritized.
Assessment for early detection of ovarian cancer can be achieved using tumor markers such as CEA, Ca 19-9, and Ca 15-3 combined with Ca-125 levels [7] [8] [9] . Other tumor markers such as Ca 72-4, OVX1, inhibin, beta-hCG, AFP, M-CSF and most recently HE 4 should also be considered for early detection of ovarian cancer [10, 11] . In this study, we wanted to examine and compare the competence of all currently used tumor markers, even though some of them measure different markers and some of them (Ca 19-9 and Ca 15-3 measure mucin) measure the same markers. Currently, Ca 125 is the most widely used and the most accurate tumor marker of ovarian cancer [4, 12] . However, serum Ca 125 has been investigated for ovarian cancer screening with conflicting results [13] . Ca 125 determination is useful for the detection of persistence and recurrence, monitoring of therapeutic effects as well as serial measurements to calculate the risk of cancer in the patients with epithelial ovarian carcinomas [14] . Levels of Ca 125 may indicate the disease extent and therefore, the likelihood of successful cyto-reductive surgery [14] . However, elevated levels of Ca 125 can also be detected in many non-malignant gynecological diseases, especially in endometriosis, and even in some physiological conditions. Numerous researchers have confirmed that Ca 125 has limitations when used to distinguish between benign and malignant ovarian masses [15] [16] [17] . The diagnostic efficiency of Ca 125 in literature usually ranges between 70 and 90% [10, 11] .
Human epididymis protein 4 is a novel serum marker which is more sensitive in the prediction of risk of ovarian malignancy than Ca125 alone in patients with a pelvic mass [18, 19] . The median Ca 125 and HE4 levels assessed together were found to be significantly higher in patients with ovarian carcinoma than in those with benign disease. Moreover, serum HE4 testing is a more powerful tool than Ca 125 assay to discriminate ovarian cancer from ovarian endometriosis and pelvic inflammatory disease, and to detect recurrence or monitor the response to therapy [20] . In addition, HE4 adds valuable information especially for premenopausal patients [21] .
According to our study, Ca 125 and HE 4 are important factors for preoperative differentiation and prediction of tumor malignancy with very high sensitivity, specificity and predictive values. However, although HE 4 was proven to be even more sensitive than Ca 125, they neither help much in differentiation between benign and borderline tumors, nor can it positively imply on the exact histopathological diagnosis of adnexal masses.
The positive rate of Ca 125 in the serous group was found to be statistically significantly higher than that in the mucinous group, while the positive rates for Ca 19-9 and CEA in mucinous histology were significantly higher than those in serous tumors. Therefore it can be concluded that the elevation of serum Ca 125 may suggest serous tumors, while the high level of serum Ca 19-9 and CEA may indicate mucinous ovarian tumors [22] . Ca19-9 is probably the most accurate tumor marker for mature cystic teratomas because it is the only tumor marker with a mean serum level above the cut-off value. As the tumor becomes bigger, this relationship becomes more distinct [23] .
We found no significant differences in the levels of Ca 19.9 and Ca 15.3 between the tumor types. There were also no significant differences in the levels of these two markers within only malignant tumors. The Ca 19.9 level was the highest in mucinous adenocarcinoma and the lowest in granulose cell tumors. On the other hand, the level of Ca 15.3 was the highest in women with endometrioid carcinoma but without statistical significance, when compared with other diagnoses. Ca 15.3 can discriminate malignant tumors from other tumor types well. Women with malignant tumors had the highest levels of CEA, especially those with mucinous adenocarcinoma and the group of "other malignant tumors". Nevertheless, there were no significant differences in the levels of CEA within malignant tumors, or between women who had benign and borderline tumors. Our results show that none of examined markers can individually imply on the exact histopathological diagnosis of malignant tumors, nor distinguish benign and borderline tumors.
Literature data show that combined multiple tumor markers, such as serum Ca 125, Ca 19.9 and mRNA for Survivin gene, can improve the overall diagnostic accuracy of all stages of primary ovarian epithelial tumors and allow a better triage between endometriosis and malignant adnexal masses [7, 24, 25] . Up until now, different risk models and screening algorithms that combine and evaluate tumor markers together, aimed at improving the specificity and sensitivity of diagnostic tests, and allowing for an effective triage of women to appropriate institutions for their care, have been developed so far. The most commonly used is Risk of Ovarian Malignancy Algorithm [ROMA] that utilizes the dual marker combination of HE4 and Ca125 appears to be the most effective at stratifying both postmenopausal and premenopausal women into high-and low-risk groups [18] . This model achieves the highest sensitivity and specificity. Furthermore, some researchers advise that in patients with an undiagnosed tumor in the pelvis, the CA-125 CEA ratio could be used to preoperatively identify a substantial fraction of patients with ovarian and non-ovarian malignancies [26] . We also confirmed that Ca 125 and HE 4 should be used together to most accurately predict the nature of adnexal masses because we also obtained highest sensitivity for the combination of Ca 125 and HE 4. On the other hand, when individual markers were evaluated, the most appropriate was Ca 125.
Moreover, we obtained another model that combines CEA and HE 4, which is the innovation brought by our research.
In conclusion, higher levels of Ca 125, HE 4, and Ca 15.3 were found to be significantly correlated with malignant tumors. Women with malignant tumors were observed to have significantly higher levels of Ca 125, CEA, and HE 4 than women with other tumor types. The Ca 19.9 level was the highest in mucinous adenocarcinoma and the lowest in granulose cell tumors. The highest levels of CEA were detected in women with mucinous adenocarcinoma and the group of "other malignant tumors". There were no significant differences in the levels of examined tumor markers within malignant tumors, or between women with benign and borderline tumors. Ca 125, HE 4, and Ca 15.3 could discriminate malignant tumors from other tumor types well. The highest sensitivity in preoperative prediction of the nature of tumors was observed using the combination of Ca 125 and HE 4. A significant model for malignancy likelihood that combines HE 4 and CEA was obtained in this study.
According to our results, blood levels of the examined tumor markers can be good predictors of the nature of adnexal masses. However, unfortunately, none of the individual markers could accurately predict the exact diagnosis of the adnexal tumor. For the most precise preoperative prognosis of the nature of adnexal tumors the combination of tumor markers should be used.
